Madrigal Pharmaceuticals (MDGL) stock surged 6.63% in the pre-market trading session on Wednesday, February 26, 2025, driven by the company's better-than-expected financial results and promising clinical trial data for its drug Rezdiffra.

The biopharmaceutical company reported fourth-quarter 2024 revenue of $103.3 million, exceeding analyst estimates of $99.1 million, and a narrower net loss of $2.71 per share compared to the expected loss of $4.12 per share. Madrigal ended the year with a strong cash position of $931.3 million.

Additionally, Madrigal announced positive two-year data from the open-label compensated MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial for Rezdiffra. Patients treated with the drug achieved a mean 6.7 kPa reduction in liver stiffness, the largest reported reduction in a compensated MASH cirrhosis population to date. This data reinforces the potential benefit of Rezdiffra in treating compensated MASH cirrhosis, an underserved patient population with no approved therapies.